Our news
- 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
- 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
- 03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Contact us
- Phone/fax: +7 495 442 37 85
- Phone: +7 985 908 58 18
- E-mail: info@regdrug.com
- pharegis.com | regdrug.com
Activities
Regulatory Events Russia
Russian Regulatory News
Pharegis LLC / ООО "Фареджис"
-
- Business address:
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
PSRN: 1157746918933
TAX ID (TIN): 7718278100
D-U-N-S: 362071645
-
- +7 495 442 37 85 9am-6pm GMT+3
-
- + 7 495 442 37 85
-
- + 7 985 908 58 18
- http://www.pharegis.com
Regulatory news
Drugs.com - New Drug Approvals
- FDA Approves Rybelsus (semaglutide), the First Oral GLP-1 Analog Treatment for Adults with Type 2 Diabetes
- FDA Approves Erleada (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
- FDA Approves Ibsrela (tenapanor) for the Treatment of Irritable Bowel Syndrome with Constipation
- FDA Approves Nucala (mepolizumab) for Six to 11-Year-Old Children with Severe Eosinophilic Asthma
News and press releases
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019, CHMP, 20/09/2019
- Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 September 2019, CVMP, 13/09/2019
- EMA to provide guidance on avoiding nitrosamines in human medicines, , 13/09/2019
- EMA to review ranitidine medicines following detection of NDMA, , 13/09/2019
Drugs.com - Clinical Trials
- FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus KENILWORTH, N.J.--(BUSINESS...
- Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen CAMBRIDGE, Mass., Sept....
- Innovation Pharmaceuticals Announces Successful Formulation of Oral Brilacidin Tablets; Upcoming Clinical Trial to Target Delivery to the Colon BEVERLY, MA –...
- Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers London, 16 September,...
Feed not found.